Company / Operating Cash Flow
Sana Biotechnology, Inc. Operating Cash Flow History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$223.2M
FY2024
5-year range
-$290.1M / -$138.0M
FY2020-FY2024
Trend
+12.0%
vs FY2023
Sector context
#177 of 216
Health Care
What the data says
Sana Biotechnology, Inc.'s operating cash flow of -$223M is lower than 82% of companies in the Health Care sector (FY2024). Improved from -$290M to -$223M over the past 2 years.
Based on SEC 10-K filings.
-$223M in FY2024.
Improved from -$290M to -$223M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 216This company -$223.2M Sector average $658.7M
▼
-133.9% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow increased 12.0% year-over-year.
- Ranks #177 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2019.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$223.2M | +12.0% |
| FY2023 | -$253.6M | +12.6% |
| FY2022 | -$290.1M | -15.5% |
| FY2021 | -$251.1M | -81.9% |
| FY2020 | -$138.0M | -61.3% |
| FY2019 | -$85.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026